By Reuters Staff
August 22, 2019
NEW YORK (Reuters Health) - The direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir is effective in patients with genotype 1 hepatitis C virus (HCV) infection after failure of treatment with sofosbuvir plus an NS5A inhibitor, according to results from a new open-label trial.
The combination of ... Read More
Hepcasia Administrator
03
Dec2019
December 3, 2019Hepcasia Administrator
26
Nov2019
KUALA LUMPUR: Twenty months after sofosbuvir, the generic Hepatitis C drug was brought into Malaysia through compulsory licensing, only some 4,500 patients have been treated, says the Health Ministry.
It admitted that this initial stage of setting the stage for screening and treatment had been saddled with many challenges.
But a lot ... Read More
November 26, 2019Hepcasia Administrator
26
Nov2019
An experimental two-part vaccine was not able to prevent chronic hepatitis C virus (HCV) infection in a mid-stage study, according to a presentation at the recent IDWeek 2019conference in Washington, DC.
Prof. Andrea Cox of Johns Hopkins University reported that study participants who received the prime-boost vaccine were no less likely to ... Read More
November 26, 2019Hepcasia Administrator
27
Sep2018
Fuelled by political will, resources for cost-effective, evidence-based prevention programmes and revolutionary advances in hepatitis C virus (HCV) treatment, momentum is building towards halting a deadly global epidemic. Worldwide, an estimated 71 million people are living with hepatitis C, a blood- borne virus that infects liver cells. Without treatment, HCV ... Read More
September 27, 2018Hepcasia Administrator
14
Aug2018
WHO published guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. For those who need more in-depth information on chronic hepatitis C treatment, this guideline can be useful. You can download from Resources under sub heading Guidelines or you can directly download from the ... Read More
August 14, 2018Hepcasia Administrator
14
Aug2018
Progress report of WHO on Access to Hepatitis Treatment: Focus on Overcoming Barriers in Low and Middle-income countries published March 2018.
Key chapters included are - status of the hepatitis C treatment, response, expanding access to hepatitis C treatment: challenges and opportunities, overcoming access to barriers: experience of selected countries from ... Read More
August 14, 2018Hepcasia Administrator
20
Mar2018
KUALA LUMPUR: Eighteen selected hospitals across the country have begun offering free Sofosbuvir-based direct-acting antiviral (DAA) therapy for treatment of Hepatitis C since early this month, according to Health Minister Datuk Seri Dr S. Subramaniam.
He said the first phase of the treatment was given to 2,000 chronic Hepatitis C patients ... Read More
March 20, 2018Hepcasia Administrator
21
Sep2017
CL ends Gilead's dangerous games with lives of HepC patients in Malaysia
Result of hard fought efforts of community-based groups, NGOs and treatment providers
20 September 2017, Bangkok and Kuala Lumpur: The Asia-Pacific Network of People living with HIV (APN+) joins the Positive Malaysian Treatment Access and Advocacy Group (MTAAG) in welcoming the ... Read More
September 21, 2017Hepcasia Administrator